- To understand the most clinically relevant open questions in the management of patients with follicular lymphoma
- To be confronted with proposed treatment algorithm in follicular lymphoma based on disease and patients’ characteristics
- To critically evaluate information from the recent clinical trials in follicular lymphoma and contextualise the results in terms of practice perspective
|Title||Duration||Content||CME Points||CME Test|
|Open Questions in the Treatment of Follicular Lymphoma||36 min.||52 slides||1||Take test|
Over the last several years, many changes occurred in the management of patients with follicular lymphoma. These changes have resulted in improved outcomes, although many unmet needs remain in this setting. Overall, the disease course is chronic, and the cure is still not possible in many cases.
In this module, the author elaborates the latest developments in the management of follicular lymphoma and focuses on clinically important issues. By emphasising currently open clinical issues, the author provides an overview of established treatments, approaches and combinations that evolved from established regimens, as well as new treatment options that have recently emerged.
This E-Learning module is a completely new edition of a previous ESMO module in which the author has expanded a list of covered topics as an attempt to summarise an intense research effort in the field of follicular lymphoma. It also provides an excellent overview of the progress made in the last years, in particular since the last edition of the module, in the management of patients with this disease.
This ESMO E-learning activity addresses the currently most relevant challenging questions that clinicians face in their practice. In particular, whether follicular lymphoma is still incurable, how early stage should be managed, if watch and wait is still acceptable, which is the best chemotherapy, whether everybody should receive rituximab maintenance, the role of chemotherapy-free options, how to treat high-risk cases, whether grade 3 follicular lymphoma should be treated differently, which are the indications for transplantation, and how to manage transformation to diffuse large B-cell lymphoma.
All data is carefully prepared and summarised from the recent clinical studies, therefore, the answers to the above open questions are drawn from the latest available evidence.
The author has reported giving talks at meetings organised by Roche, Sandoz, Millennium and Mundipharma.